Clavis Pharma Articles
Clavis Pharma stops elacytarabine development on negative Ph III trial in acute myeloid leukemia
2 April 2013
Clavis Pharma and Clovis Oncology sign new $205 million deal for pancreatic cancer drug in Asia and rest of world
11 November 2010
Showing 1-4 of 4 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
